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INTRODUCTION
Children with moderate-to-severe inflammatory 
bowel disease (IBD), including Crohn’s disease 
and ulcerative colitis, often require biologic 
medications administered via infusions to 
manage their disease adequately. A common and effective 
biologic used for this purpose is infliximab, a chimeric 
monoclonal antibody against tumor necrosis 
factor-α. Time spent receiving these infu-
sions in the hospital setting disrupts school, 
extracurricular activities, time spent 
at home, and other aspects of normal 
childhood development. Hospital-based 
infusions also expose patients to nosoco-
mial pathogens and potential infection. 
Significant nursing time can also be spent 
in hospital-based infusions, tying up needed 
hospital resources.
Because infliximab is a biologic medication, 
its administration carries a small risk of a severe hyper-
sensitivity reaction including anaphylaxis.1 There is vari-
ation in infliximab administration practices in the United 
States.2 However, there is good evidence in the literature 
demonstrating that rapid infliximab infusions 60 minutes 
in duration are safe after a child has reached the main-
tenance phase of his treatment with no prior symptoms 
of an infusion reaction.3–5 Shorter infusions may be safer 
according to the results of a Canadian study from 2011.6
The goal of this quality improvement (QI) project was 
to implement a standard practice in a Midwestern chil-
dren’s hospital in which all eligible IBD patients would 
receive rapid infliximab infusions with a standardized 
process, thereby decreasing the average time spent at the 
hospital by patients and their families. We also hoped to 
simultaneously improve patient quality of life, patient 
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Introduction: Children with inflammatory bowel disease (IBD) often require infliximab infusions to manage their disease. 
Infusions administered in the hospital setting require the patient and their families to devote many hours away from home. 
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monitored. Conclusions: Implementation of a rapid infliximab infusion protocol made an impressive impact on freed family time 
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satisfaction, and the efficiency of health care delivery, 
though we did not formally asses these metrics. If this 
intervention were to be adopted broadly, it could substan-
tially decrease the cumulative hours children with IBD 
and their families spend receiving infusions in hospital 
settings nationwide. An executive sponsor supported the 
project, and it was completed as part of the Intermediate 
Improvement Science Series, supported by Cincinnati 
Children’s Hospital Medical Center.
METHODS
We undertook this project in a medium-sized free-stand-
ing children’s hospital in the Midwest. In our institution at 
the project’s inception, 5 physicians cared for patients with 
IBD). Our population of patients with IBD slowly increased 
throughout this project, given patients were newly diag-
nosed, and incorporated into our data collection. At the 
beginning of the project, our population consisted of ap-
proximately 140 IBD patients, with approximately 50 re-
ceiving infliximab infusions, and 28 eligible for rapid infu-
sions (RIs) based on our protocol. These patients received 
infusions every 4–8 weeks, depending on clinical dictate.
An interdisciplinary team consisting of 5 pediatric gas-
troenterologists, a gastroenterology nurse, an infusion 
nurse educator, an infusion nurse, a clinical pharmacist, 
a QI consultant, and an executive sponsor began meet-
ing in July 2014 to address this project specifically. The 
QI framework was implemented to create a smart aim: 
to decrease the average door-to-door time for eligible 
children to receive rapid infliximab infusions from 279 
minutes (4 hours 39 minutes) to 137 minutes (2 hours 
17 minutes) over a 6-month period (Fig. 1). We set this 
goal from best case scenario modeling plus a 10% buffer. 
We define door-to-door time as when patients are regis-
tered to when they have been discharged; both were time 
stamped in the electronic medical record (EMR) and 
manually extracted. We identified key drivers and popu-
lated corresponding interventions, presented in an interim 
key driver diagram, complete with SMART (Specific, 
Measurable, Actionable, Relevant, Time-bound) aim (Fig. 
1). Plan-do-study-act cycles (PDSAs; Fig. 2) which are an 
iterative, problem-solving modeling tool commonly used 
in QI work, allowed the team to learn from early failures 
and successes and provided a framework for spreading 
successful changes.
Fig. 1. KDD, including SMART (Specific, Measurable, Actionable, Relevant, Time-bound) aim. EMR indicates electronic medical re-
cord; KDD, key driver diagram; LOR, level of reliability.
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Chart reviews, confirmed with direct clinical observa-
tion, provided overall door-to-door times and interval 
steps of a typical patient’s infusion visit including registra-
tion, medication preparation, preinfusion nursing assess-
ment, preinfusion preparation, infusion, postinfusion 
observation, and discharge (see Pareto chart, Fig.  3A). 
The Pareto chart guided the team toward those steps in 
the process (primarily the times of infusion and postin-
fusion observation) where we could attain the largest 
improvements.
Previous research has shown that RIs are safe.3,6 A pri-
mary intervention of this project included the transition 
of eligible patients to RI to decrease door-to-door times 
in the hospital. To be eligible, patients needed their first 3 
induction infusions plus 1 maintenance infusion complete 
without any evidence of an infusion reaction.3 Written 
handouts were given to families in the form of letters, and 
discussed with families in the clinic setting and at infusions 
via standardized scripting before making the transition. 
We trained nurses and physicians to use the standardized 
scripting before transitioning patients. Patients, families, or 
medical treatment teams could opt out of RIs at any point 
throughout this QI project for safety or any other concerns.
We describe interventions in the Results section below. 
We gathered data to assess the efficiency and safety of 
the new process. The primary outcome measure was 
the door-to-door infliximab infusion times within the 
observation unit of the hospital. We used Microsoft 
PowerPoint, Excel, and Word to create a smart aim, 
key driver diagram, PDSA ramps, simplified failure 
mode effects analysis (Supplementary Digital Content 1, 
Figure 1, http://links.lww.com/PQ9/A66), statistical pro-
cess control charts, and other tools that aided in data 
analysis, interpretation, and communication among 
target populations.
The changes above were implemented initially on a 
small scale, and each analyzed within a PDSA frame-
work. We made slight adjustments through several tests 
of change, at each iteration gaining more momentum 
and buy-in for broader application. We created a control 
chart with the data collected on door-to-door times be-
fore the project initiation (ie, for baseline data), during 
each test of change, and throughout the maintenance 
phase covering a 6-month period (Fig. 4). Each data point 
in Fig. 4 represents the measured minutes of a single in-
fusion visit. After the 6-month period ended, data were 
collected on a less frequent basis (via a standard sam-
pling frame) to ensure stability and to ensure that we 
sustained gains.
There were no anticipated ethical concerns before start-
ing this QI initiative, nor did we uncover any throughout. 
There were no conflicts of interest. Our local institutional 
review board approved this project as being a nonresearch, 
QI initiative, and thus did not undergo a full committee 
review. We employed SQUIRE (Standards for QUality 
Improvement Reporting Excellence) 2.0 Guidelines in the 
creation of this article.
RESULTS
Within 2 months of testing the standard order set, elim-
inating a postinfusion observation period (EO), and 
transitioning those eligible patients to RIs, the average 
door-to-door time decreased from a mean of 279 min-
utes (4 hours 39 minutes) to 202 minutes (3 hours 22 
minutes), just 65 minutes longer than the initial SMART 
aim goal. One month later, following 2 more PDSAs, in-
cluding broader application, the average door-to-door 
time decreased further to 151 minutes (2 hours 31 min-
utes), only 14 minutes longer than the smart aim goal 
(Fig.  4). We have sustained these improvements over 
multiple years.
An examination of the time obtained for each step of 
the new infusion process is presented in a Pareto chart 
as Fig. 3B. These data were taken from a sampling of 3 
patients in October 2018 and demonstrates gains in vir-
tually all steps of the process.
Using the difference in means from the control chart, 
we determined that these changes saved roughly 13 hours 
of nursing time each week. This time saved allowed for 
46% more time for infusion patients. Even more impor-
tantly, these changes allowed for 128 minutes (2 hours 8 
minutes) of freed family time. An additional benefit in-
cluded less administration time spent in order placement 
through the use of a standard order set. We estimate that 
120 hours were spent in planning, undertaking PDSAs, 
data analysis, and implementation efforts.
Concerning balancing measures, there were no ad-
verse events, including no infusion reactions, in patients 
who received RIs during data collection. We received no 
reports of decreased quality or safety concerns from fami-
lies or staff. Review of office visit documentation after RIs 
revealed no safety or quality concerns, including those 
items listed above.
Interventions
The initial change in moving toward rapid infliximab 
infusions involved creating a standardized order set 
within the institution’s EMR. The goal of this order set 
was to simplify the process of placing infliximab infusion 
orders for the gastroenterologists on staff and making 
the orders more standardized regardless of provider. The 
typical dosing of medications (including premedications 
and infliximab), the infusion rate, and the multitude of 
nursing orders were all included. The order set made the 
front-end work more efficient and also supported the up-
coming change toward RIs. The specific orders for each 
patient became more standardized and could be better 
anticipated by the infusion nursing staff as they prepared 
for the visit and cared for the patients throughout their 
infusions.
The next change was 2-fold: transitioning all eligible 
patients to RIs and eliminating the 30-minute postinfu-
sion EO. The RI meant cutting the actual infusion time 
in half from 120–60 minutes. This change, plus the EO, 
meant 90 minutes of the door-to-door time would be 
Decreasing Door-to-Door Times for Infliximab Infusions
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Fig. 2. Plan-do-study-act (PDSA) cycles. A, Sample PDSA worksheet for the transition to rapid infusion. B, PDSA Ramp: transition 
eligible patients/default to rapid infusions. IFX, Infliximab; GI, Gastroenterology.
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Fig. 3. Pareto charts of door-to-door time spent by families who receive infliximab infusions at the start of the project in July 2014 (A) 
and in October 2018 (B). DCH, Dayton Children’s Hospital; IFX, Infliximab.
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reduced via this change alone. We had no infusion reac-
tions in the preceding 2 years before the start of this QI 
project.
Four months from the start of the project, an additional 
change was made within the institution’s pharmacy to im-
prove the efficiency of infusion preparation and further 
reduce the average patient door-to-door time. The phar-
macy built a physical pass-through window in the wall 
adjacent to the infusion medication preparation area. 
Before this change, pharmacy technicians would have to 
don and doff personal protective equipment, sometimes 
repeatedly, during the preparation of an infliximab infu-
sion if items needed were forgotten outside that room. 
After this change, other pharmacy staff could easily hand 
a needed item through the pass-through window to the 
technician preparing the infusion, thus making the entire 
process more efficient.
DISCUSSION
This study showed a statistically significant decrease in 
average door-to-door times for patients receiving inflix-
imab infusions in a children’s hospital observation unit. 
The initial 90-minute decrease was expected given the 
shorter infusion time and omitting the postinfusion EO. 
There were an additional 38 minutes of time saved thanks 
to improved efficiency and familiarity with the new 
protocol. The 2 hours 8 minutes of freed time could be 
returned to the patients and their families. For a patient 
who receives 6 infliximab infusions per year, a total time 
savings of 768 minutes (12 hours 48 minutes) per year 
could be amassed. Children with chronic disease spend 
more time in healthcare settings (emergency department, 
primary care, specialty clinics, and hospitals), and their 
care represents a substantial financial burden, than com-
pared with those without a chronic disease.7–11 This re-
ality impacts home life, school life, developmental aspects, 
and social growth. By returning this time to patients and 
their families, we give back a part of childhood stolen 
by IBD. Further steps toward a home-based or exter-
nal-based infusions would further improve quality of life, 
and efforts are currently underway across the country to 
ensure this is done safely.12
As with most changes, there is often resistance at the 
start. We found that reminding the physicians to utilize 
the new order set, familiarizing nursing staff with changes 
in their orders, and getting the pharmacy involved in more 
efficient infusion preparation were all challenges initially. 
The culture change toward default RIs was surprisingly 
quick, however. Even with standardized scripting and ad-
equate forewarning for patients’ families, there was still 
some hesitation, given concern for infusion reactions. The 
Fig. 4. Statistical process control chart with annotations. EO indicates eliminate observation; RI, rapid infusion start; SOS, standard-
ized order set.
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standardized scripting was thought to help prevent unin-
tended variation in the initiatives, and improve communi-
cation between families and care teams.
This QI effort has several important limitations. First, 
we collected multiple data by hand. All attempts were 
made to ensure data accuracy, but there remains a pos-
sibility of human error. Second, we were reliant on our 
EMR for the timing of entries. Multiple reasons could 
have delayed a patient before their first official entry into 
our system, and evaded capture in our recording of data. 
Third, this was a project at a single center, which may 
compromise external validity. Smaller institutions tend to 
have less representation in the medical literature, how-
ever, and we felt the lessons learned here could be gener-
alizable to other smaller institutions and also applicable 
to larger pediatric facilities.
We want to emphasize that this project did not reveal 
any patient safety concerns after adopting a RI protocol. 
A study at Stanford in 2017 yielded no safety concerns 
over a 2-year period of rapid infliximab infusions.13 
Implementation of rapid infliximab infusion protocols 
nationwide could result in a considerable amount of 
freed time for IBD patients. Our QI work at a smaller 
free-standing children’s hospital suggests rapid improve-
ment is possible with small sustained efforts. Our re-
turn on investment is roughly 1 hour invested for 1 hour 
returned for every 10 patients. In our eligible population 
for RIs, this equates to a 7-fold return of time for every 
hour of medical team investment.
Implementing a rapid infliximab infusion protocol at 
our institution was associated with decreased average 
door-to-door times for patients with IBD and their fam-
ilies, thus freeing up patient time for activities outside 
the hospital and improving the efficiency of health care 
delivery. We continue to look for ways to improve the 
quality of life for children with chronic disease.
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